Instructions for Ceraxon (Citicoline)
English product name
Ceraxon®
Release form
500 mg/4 ml r/d/w and b/m: amp. 5 pcs.
1000 mg/4 ml r/d/w and v/m injection: amp. 5 pcs.
Description
The solution for in/in and in/m injection is a transparent colorless liquid.
1 amp
sodium cyticoline 1045 mg,
which corresponds to the content of cyticoline 1000 mg
Auxiliary substances: chlorohydric acid 1 M or sodium hydroxide 1 M - up to pH 6.5-7.1, water d/i - up to 4 ml.
4 ml - colorless glass ampoules (5) - packages, loop (1) - cardboard packs.
ATC codes
N06BX06 Citicoline
Clinical-pharmacological groups / Group affiliation
Nootropic preparation
Active substance
tsitikolin
Pharmacotherapy group Ceraxon
Nootropic agent
Storage Conditions
The drug Citicoline should be stored in a place inaccessible to children at a temperature not higher than 30 ° C.
Best before date Ceraxon
The shelf life is three years.
Testimony Citicoline:
- Acute period of ischemic stroke (as part of complex therapy);
- The recovery period of ischemic and haemorrhagic strokes;
- Traumatic brain injury, acute (as part of complex therapy) and recovery period;
- Cognitive and behavioural disorders in degenerative and vascular brain diseases.
Method of use, course and dosage Citicoline:
inside the venno, the drug is administered in the form of a slow injection (within three to five minutes, depending on the dose) or a drip infusion (forty to sixty drops/min). inside the venno, the injection path is preferable to that in/m. The re-administration of the drug Citicoline in the same place should be avoided.
Acute period of ischemic stroke and brain injury: the recommended dose is 1000 mg every twelve hours from the first day after diagnosis; Treatment duration is at least six weeks. Three to five days after the start of treatment (if swallowing function is not impaired), it is possible to switch to oral forms of Ceraxon®.
The recovery period of ischemic and haemorrhagic strokes, the recovery period for brain injury, cognitive and behavioural disorders for degenerative and vascular diseases of the brain: The recommended dose is 500-2000 mg/day (five - ten ml once - twice a day). The dose and duration of treatment depends on the severity of the symptoms.
Elderly patients do not need a dose correction of Ceraxon® in the vein or in the body.
The solution for in-line and in-line administration in the ampoule is intended for single use. After opening the ampoule, use the solution immediately. The drug Citicoline is compatible with all species within venno isotonic solutions and dextrose solutions.
Application in elderly patients
Elderly patients do not need a dose correction of Ceraxon®.
Use in children
It is contraindicated in children and adolescents under 18 years of age.
- Nosology (ICD codes)
- F07
- Personality and behavioural disorders caused by disease, damage or brain dysfunction
- I61
- Intracerebral hemorrhage (haemorrhagic type disorder)
- I63
- Brain infarction
- I69
- Effects of cerebrovascular disease
- S06
- Intracranial injury
- T90
- Effects of head injuries
Pharmacological effect Ceraxon:
Nootropic drug Citicoline. Citicoline, a precursor of key ultracostructural components of the cell membrane (mainly phospholipids), has a wide range of action: promotes repair of damaged cell membranes, inhibits the action of phospholipase, preventing excessive formation of free radicals, and prevents cell death by acting on the mechanisms of apoptosis.
In the acute stroke period, Citicoline reduces the amount of damage to brain tissue and improves cholinergic transmission.
In traumatic brain injury, it reduces the duration of the post-traumatic coma and the expression of neurological symptoms, and cyticoline contributes to a reduction in the length of the recovery period.
In chronic hypoxia in the brain, Citicoline is effective in the treatment of cognitive disorders such as memory impairment, lack of initiative, and difficulties in performing everyday activities and self-care. It increases attention and consciousness and reduces amnesia.
Ceraxon® is effective in the treatment of sensitive and motor neurological disorders of degenerative and vascular etiology.
